Hemogenyx Pharmaceuticals PLC Announces Placing to raise £340,000
Hemogenyx Pharmaceuticals (LSE:HEMO) has successfully raised £340,000 through a placing of 100,000 new ordinary shares at 340p per share. The institutional investor participating in the placing has also received 50,000 warrants, exercisable at 500p each from March 1, 2025, for a 12-month period.
The proceeds will fund the clinical trial of HG-CT-1, the company's lead asset targeting relapsed/refractory acute myeloid leukemia (AML) in adults. The first patient is currently being evaluated for trial inclusion. Trading of the new shares on the London Stock Exchange's Main Market is expected around January 15, 2025.
Following the admission, the company's enlarged issued share capital will comprise 3,604,539 ordinary shares, with no shares held in treasury. The new shares will rank equally with existing ordinary shares.
Hemogenyx Pharmaceuticals (LSE:HEMO) ha raccolto con successo 340.000 sterline tramite l'emissione di 100.000 nuove azioni ordinarie a 340p per azione. L'investitore istituzionale che ha partecipato all'emissione ha inoltre ricevuto 50.000 warrant, esercitabili a 500p ciascuno a partire dal 1° marzo 2025, per un periodo di 12 mesi.
I proventi finanzieranno il trial clinico di HG-CT-1, il principale asset dell'azienda che mira a trattare la leucemia mieloide acuta (AML) in fase di recidiva/resistenza negli adulti. Attualmente, il primo paziente è in fase di valutazione per l'inclusione nello studio. La quotazione delle nuove azioni sul Mercato Principale della Borsa di Londra è prevista intorno al 15 gennaio 2025.
In seguito all'ammissione, il capitale sociale emesso dell'azienda sarà composto da 3.604.539 azioni ordinarie, senza azioni detenute in tesoreria. Le nuove azioni avranno lo stesso rango delle azioni ordinarie esistenti.
Hemogenyx Pharmaceuticals (LSE:HEMO) ha logrado recaudar con éxito 340.000 libras esterlinas mediante la colocación de 100.000 nuevas acciones ordinarias a 340p cada una. El inversor institucional que participó en la colocación también ha recibido 50.000 warrants, canjeables a 500p cada uno desde el 1 de marzo de 2025, por un período de 12 meses.
Los fondos se destinarán a financiar el ensayo clínico de HG-CT-1, el activo principal de la compañía que se dirige a la leucemia mieloide aguda (AML) en adultos con recaída/resistencia. Actualmente, se está evaluando al primer paciente para su inclusión en el ensayo. Se espera que la cotización de las nuevas acciones en el Mercado Principal de la Bolsa de Londres tenga lugar alrededor del 15 de enero de 2025.
Tras la admisión, el capital social emitido de la empresa estará compuesto por 3.604.539 acciones ordinarias, sin acciones en tesorería. Las nuevas acciones tendrán el mismo rango que las acciones ordinarias existentes.
Hemogenyx Pharmaceuticals (LSE:HEMO)는 100,000주 신규 보통주를 발행하여 주당 340p에 340,000 파운드를 성공적으로 모금했습니다. 이번 발행에 참여한 기관 투자자는 2025년 3월 1일부터 12개월 동안 각각 500p에 행사 가능한 50,000개의 워런트도 받았습니다.
모금된 자금은 성인의 재발/난치성 급성 골수성 백혈병(AML)을 겨냥한 회사의 주요 자산인 HG-CT-1의 임상 시험을 위한 것입니다. 현재 첫 환자가 시험 참여를 위해 평가받고 있습니다. 새로운 주식은 2025년 1월 15일경 런던 증권거래소의 주요 시장에서 거래될 것으로 예상됩니다.
상장 이후, 회사의 확대된 발행 주식 자본은 3,604,539주의 보통주로 구성되며, 자산은 없을 것입니다. 새 주식은 기존 보통주와 동등한 순위를 가집니다.
Hemogenyx Pharmaceuticals (LSE:HEMO) a réussi à lever 340 000 livres sterling par le biais d'un placement de 100 000 nouvelles actions ordinaires à 340p chacune. L'investisseur institutionnel participant au placement a également reçu 50 000 bons de souscription, exerçables à 500p chacun à partir du 1er mars 2025, pendant une période de 12 mois.
Les fonds seront utilisés pour financer l'essai clinique de HG-CT-1, le principal actif de l'entreprise ciblant la leucémie myéloïde aiguë (LMA) chez les adultes en récidive/résistance. Le premier patient est actuellement en cours d'évaluation pour une éventuelle inclusion dans l'essai. Le début des échanges des nouvelles actions sur le marché principal de la Bourse de Londres est prévu autour du 15 janvier 2025.
Après l'admission, le capital social émis de la société comprendra 3 604 539 actions ordinaires, sans actions détenues en trésorerie. Les nouvelles actions auront le même rang que les actions ordinaires existantes.
Hemogenyx Pharmaceuticals (LSE:HEMO) hat erfolgreich 340.000 Pfund durch die Platzierung von 100.000 neuen Stammaktien zu je 340p raised. Der institutionelle Investor, der an der Platzierung beteiligt war, erhielt außerdem 50.000 Warrants, die ab dem 1. März 2025 für einen Zeitraum von 12 Monaten zu je 500p ausgeübt werden können.
Die Einnahmen werden die klinische Studie von HG-CT-1 finanzieren, dem wichtigsten Vermögenswert des Unternehmens, der sich auf rezidivierende/resistente akute myeloische Leukämie (AML) bei Erwachsenen konzentriert. Der erste Patient wird derzeit auf die Teilnahme an der Studie bewertet. Der Handel mit den neuen Aktien am Hauptmarkt der Londoner Börse wird voraussichtlich um den 15. Januar 2025 beginnen.
Nach der Zulassung wird das erweiterte ausgegebene Aktienkapital des Unternehmens aus 3.604.539 Stammaktien bestehen, wobei keine Aktien im eigenen Bestand gehalten werden. Die neuen Aktien werden gleichwertig mit den bestehenden Stammaktien eingestuft.
- Secured £340,000 in new funding through share placement
- First patient being evaluated for HG-CT-1 clinical trial
- Additional warrant coverage at 500p provides potential for future funding
- Dilution of existing shareholders through new share issuance
- Small funding amount may require additional capital raises in the future
LONDON, UK / ACCESSWIRE / January 8, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has raised £340,000 through the issue of 100,000 new ordinary shares ("Placing Shares") at a price of 340p per share (the "Placing"). One institutional investor has subscribed for the Placing Shares and has also been granted 50,000 warrants exercisable at a price of 500p each for a period of 12 months from 1 March 2025.
The Placing uses the Company's current headroom to issue ordinary shares for cash. The net proceeds of the Placing will be dedicated to the clinical trial of the Company's lead asset, HG-CT-1, targeting relapsed/refractory (R/R) acute myeloid leukemia (AML) in adults. The first patient for the trial is recruited and being tested for inclusion/exclusion criteria to satisfy the clinical protocol. The funds raised will also assist the Company into the next stage of the trials.
An application is being made to the Main Market of the London Stock Exchange, and admission of the Placing Shares to trading is expected on or around 15 January 2025 ("Admission"). The Placing Shares will rank pari passu with the Company's existing Ordinary Shares.
Total Voting Rights
For the purpose of the Disclosure Guidance and Transparency Rules, following Admission the enlarged issued share capital of the Company will comprise 3,604,539 ordinary shares. The Company does not hold any shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
|
|
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
|
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on accesswire.com
FAQ
How much did Hemogenyx Pharmaceuticals (LSE:HEMO) raise in its January 2025 placing?
What is the purpose of Hemogenyx's January 2025 fundraising?
What warrants were issued with the January 2025 placing?
When will the new Hemogenyx placing shares begin trading?
What will be Hemogenyx's total shares outstanding after the January 2025 placing?
